Myomo, Inc. (NYSE:MYO) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA Investor Relations Paul Gudonis - CEO Dave Henry - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Scott Henry - AGP Anthony Vendetti - Maxim Group Ben Haynor - Lake Street Capital Markets Edward Woo - Ascendiant Capital Operator Good day, and welcome to the Myomo Third Quarter 2024 Financial Results Conference Call. [Operator Instructions]. I would now like to turn ...

Myomo, Inc. (MYO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.03, delivering a surprise of 57.14%.Over the last four quarters, the company has surpassed consen ...

4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 47-0944526 (State or Other Jurisdictio ...

Exhibit 99.1 Myomo Reports Record Third Quarter Financial and Operating Results $9.2 million in revenue, raises full-year revenue guidance 225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end 645 additions to the pipeline result in 1,263 patients in the pipeline as of September 30, 2024 BOSTON (November 6, 2024) – Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurologi ...

Myomo, Inc. (NYSE:MYO) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Scott Henry - AGP Anthony Vendetti - Maxim Group Edward Woo - Ascendiant Capital Ben Haynor - Lake Street Capital Markets Operator Good day and welcome to Myomo's Second Quarter of 2024 Earnings Call. All participants ...

INVESTOR PRESENTATION AUGUST 2024 Paul R. Gudonis, Chairman and CEO David Henry, CFO Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSE American: MYO 1 NYSE American: MYO Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company's common stock on the NYSE American, the Company's plans for the use of proceeds and advancing its product li ...

4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 47-0944526 (State or Other Jurisdiction of ...

Exhibit 99.1 Myomo Reports Second Quarter 2024 Financial Results Record revenue of $7.5 million Record 213 MyoPro® authorizations and orders Record 550 additions to the pipeline, with 1,179 patients in the pipeline at quarter-end BOSTON (August 6, 2024) – Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upperlimb paralysis, today announced financial results for the three an ...

designed for long-term use in the home. Then on April 1, the new pricing determined by CMS went into effect with reimbursement for the MyoPro Motion-G at 65,872 and the MyoPro Motion-W at 33,481. These decisions by CMS opened a new world for stroke survivors and others with neurological injury or disease by increasing access to the MyoPro for the many patients enrolled in standard fee-for-service Medicare, or Part B. Prior to this clarity on reimbursement, we are not able to provide a MyoPro to traditional ...

Exhibit 99.1 Myomo Reports First Quarter 2024 Financial Results Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 8, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from ...